Evidence map›Paper›PMID 39556603›Full record

ArticlePLoS computational biology2024

Integrative pan-cancer analysis reveals a common architecture of dysregulated transcriptional networks characterized by loss of enhancer methylation.

Jørgen Ankill, Zhi Zhao, Xavier Tekpli, Elin H Kure, Vessela N Kristensen, Anthony Mathelier, Thomas Fleischer

Abstract read
In one paragraph

Article in PLoS computational biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jørgen AnkillDepartment of Cancer Genetics, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-5752-0299
Zhi ZhaoDepartment of Cancer Genetics, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0003-2325-1438
Xavier TekpliInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Elin H KureDepartment of Cancer Genetics, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway.
Vessela N KristensenInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Anthony MathelierDepartment of Medical Genetics, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-5127-5459
Thomas FleischerDepartment of Cancer Genetics, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0003-0985-8460

Funding

South-Eastern Norway Regional Health Authority
6 · The paper itself

Abstract

Aberrant DNA methylation contributes to gene expression deregulation in cancer. However, these alterations' precise regulatory role and clinical implications are still not fully understood. In this study, we performed expression-methylation Quantitative Trait Loci (emQTL) analysis to identify deregulated cancer-driving transcriptional networks linked to CpG demethylation pan-cancer. By analyzing 33 cancer types from The Cancer Genome Atlas, we identified and confirmed significant correlations between CpG methylation and gene expression (emQTL) in cis and trans, both across and within cancer types. Bipartite network analysis of the emQTL revealed groups of CpGs and genes related to important biological processes involved in carcinogenesis including proliferation, metabolism and hormone-signaling. These bipartite communities were characterized by loss of enhancer methylation in specific transcription factor binding regions (TFBRs) and the CpGs were topologically linked to upregulated genes through chromatin loops. Penalized Cox regression analysis showed a significant prognostic impact of the pan-cancer emQTL in many cancer types. Taken together, our integrative pan-cancer analysis reveals a common architecture where hallmark cancer-driving functions are affected by the loss of enhancer methylation and may be epigenetically regulated.

Indexed as

CpG IslandsDNA MethylationEnhancer Elements, GeneticGene Expression Regulation, NeoplasticGene Regulatory NetworksNeoplasmsQuantitative Trait LociComputational BiologyEpigenesis, GeneticHumans

Identifiers

PMID39556603
PMCPMC11611269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.